{
  "captured_at": "2025-10-26T15:09:37.232364+00:00",
  "search_term": "King denborough",
  "search_resolution": {
    "normalized_condition": "king denborough",
    "mesh_terms": [
      "King Denborough syndrome",
      "King syndrome"
    ],
    "reused_cached": false,
    "search_term_id": 1,
    "query_payload": {
      "normalized_query": "king denborough",
      "esearch": {
        "ids": [
          "67536883"
        ],
        "translation": null,
        "primary_id": "67536883",
        "query": "((\"King Denborough syndrome\"[mesh] OR \"King syndrome\"[mesh]) OR (\"King Denborough syndrome\"[tiab] OR \"King syndrome\"[tiab])) AND (((\"Anesthesia\"[mesh] OR \"Anesthesia, General\"[mesh] OR \"Anesthesia, Conduction\"[mesh] OR \"Anesthetics\"[mesh] OR \"Anesthesiology\"[mesh] OR \"Analgesia\"[mesh] OR \"Analgesia, Epidural\"[mesh] OR \"Conscious Sedation\"[mesh] OR \"Monitoring, Intraoperative\"[mesh] OR \"Pain, Postoperative\"[mesh]) OR (\"anesthesia\"[tiab] OR \"anaesthesia\"[tiab] OR \"anesthetic\"[tiab] OR \"anesthetics\"[tiab] OR \"sedation\"[tiab] OR \"conscious sedation\"[tiab] OR \"regional anesthesia\"[tiab] OR \"nerve block\"[tiab] OR \"perioperative\"[tiab] OR \"induction of anesthesia\"[tiab] OR \"general anesthesia\"[tiab] OR \"postoperative pain\"[tiab])) OR ((\"Anesthetics, Intravenous\"[mesh] OR \"Anesthetics, Local\"[mesh] OR \"Anesthetics, Inhalation\"[mesh] OR \"Analgesics, Opioid\"[mesh] OR \"Analgesics, Non-Narcotic\"[mesh] OR \"Neuromuscular Blocking Agents\"[mesh] OR \"Hypnotics and Sedatives\"[mesh]) OR (\"propofol\"[tiab] OR \"ketamine\"[tiab] OR \"midazolam\"[tiab] OR \"fentanyl\"[tiab] OR \"remifentanil\"[tiab] OR \"dexmedetomidine\"[tiab] OR \"sevoflurane\"[tiab] OR \"isoflurane\"[tiab] OR \"desflurane\"[tiab] OR \"rocuronium\"[tiab] OR \"succinylcholine\"[tiab] OR \"bupivacaine\"[tiab] OR \"lidocaine\"[tiab])))"
      },
      "esummary": {
        "primary_id": "67536883",
        "mesh_terms": [
          "King Denborough syndrome",
          "King syndrome",
          "King-Denborough Syndrome",
          "Anesthetic-induced malignant hyperpyrexia in children"
        ]
      },
      "ranked_mesh_terms": [
        {
          "term": "King Denborough syndrome",
          "normalized": "king denborough syndrome",
          "overlap": 2,
          "jaccard": 0.6667,
          "rank": 0,
          "extra_tokens": [
            "syndrome"
          ],
          "token_sequence": [
            "king",
            "denborough",
            "syndrome"
          ]
        },
        {
          "term": "King-Denborough Syndrome",
          "normalized": "king-denborough syndrome",
          "overlap": 2,
          "jaccard": 0.6667,
          "rank": 2,
          "extra_tokens": [
            "syndrome"
          ],
          "token_sequence": [
            "king",
            "denborough",
            "syndrome"
          ]
        },
        {
          "term": "King syndrome",
          "normalized": "king syndrome",
          "overlap": 1,
          "jaccard": 0.3333,
          "rank": 1,
          "extra_tokens": [
            "syndrome"
          ],
          "token_sequence": [
            "king",
            "syndrome"
          ]
        },
        {
          "term": "Anesthetic-induced malignant hyperpyrexia in children",
          "normalized": "anesthetic-induced malignant hyperpyrexia in children",
          "overlap": 0,
          "jaccard": 0.0,
          "rank": 3,
          "extra_tokens": [
            "anesthetic",
            "children",
            "hyperpyrexia",
            "in",
            "induced",
            "malignant"
          ],
          "token_sequence": [
            "anesthetic",
            "induced",
            "malignant",
            "hyperpyrexia",
            "in",
            "children"
          ]
        }
      ]
    },
    "mesh_terms_used": [
      "King Denborough syndrome",
      "King syndrome"
    ]
  },
  "pubmed_search": {
    "query": "((\"King Denborough syndrome\"[mesh] OR \"King syndrome\"[mesh]) OR (\"King Denborough syndrome\"[tiab] OR \"King denborough\"[tiab] OR \"King syndrome\"[tiab] OR \"king denborough\"[tiab])) AND (((\"Anesthesia\"[mesh] OR \"Anesthesia, General\"[mesh] OR \"Anesthesia, Conduction\"[mesh] OR \"Anesthetics\"[mesh] OR \"Anesthesiology\"[mesh] OR \"Analgesia\"[mesh] OR \"Analgesia, Epidural\"[mesh] OR \"Conscious Sedation\"[mesh] OR \"Monitoring, Intraoperative\"[mesh] OR \"Pain, Postoperative\"[mesh]) OR (\"anesthesia\"[tiab] OR \"anaesthesia\"[tiab] OR \"anesthetic\"[tiab] OR \"anesthetics\"[tiab] OR \"sedation\"[tiab] OR \"conscious sedation\"[tiab] OR \"regional anesthesia\"[tiab] OR \"nerve block\"[tiab] OR \"perioperative\"[tiab] OR \"induction of anesthesia\"[tiab] OR \"general anesthesia\"[tiab] OR \"postoperative pain\"[tiab])) OR ((\"Anesthetics, Intravenous\"[mesh] OR \"Anesthetics, Local\"[mesh] OR \"Anesthetics, Inhalation\"[mesh] OR \"Analgesics, Opioid\"[mesh] OR \"Analgesics, Non-Narcotic\"[mesh] OR \"Neuromuscular Blocking Agents\"[mesh] OR \"Hypnotics and Sedatives\"[mesh]) OR (\"propofol\"[tiab] OR \"ketamine\"[tiab] OR \"midazolam\"[tiab] OR \"fentanyl\"[tiab] OR \"remifentanil\"[tiab] OR \"dexmedetomidine\"[tiab] OR \"sevoflurane\"[tiab] OR \"isoflurane\"[tiab] OR \"desflurane\"[tiab] OR \"rocuronium\"[tiab] OR \"succinylcholine\"[tiab] OR \"bupivacaine\"[tiab] OR \"lidocaine\"[tiab])) OR (\"King denborough\"[tiab] OR \"king denborough\"[tiab]))",
    "pmids": [
      "33190635",
      "30406384",
      "31040503",
      "39966651",
      "21514828",
      "37783627",
      "2907859",
      "27918309",
      "11345752",
      "12364941",
      "1483040",
      "12826552",
      "24951453",
      "1508238",
      "3245876",
      "1415346",
      "18765655",
      "3374516",
      "36965156",
      "11758332",
      "11596430"
    ],
    "article_count": 21,
    "fallback_used": false
  },
  "articles": [
    {
      "pmid": "33190635",
      "rank": 1,
      "score": 6.74,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 8008,
      "preferred_url": "https://doi.org/10.1186/s13395-020-00243-4",
      "title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature."
    },
    {
      "pmid": "30406384",
      "rank": 2,
      "score": 5.96,
      "content_source": "pmc-full-text",
      "has_content": true,
      "token_estimate": 8441,
      "preferred_url": "https://doi.org/10.1007/s13311-018-00677-1",
      "title": "Ryanodine Receptor 1-Related Myopathies: Diagnostic and Therapeutic Approaches."
    },
    {
      "pmid": "31040503",
      "rank": 3,
      "score": 3.99,
      "content_source": "pubmed-abstract",
      "has_content": true,
      "token_estimate": 108,
      "preferred_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461318/",
      "title": "Malignant Hyperthermia."
    },
    {
      "pmid": "39966651",
      "rank": 4,
      "score": 3.3600000000000003,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1038/s41431-025-01795-z",
      "title": "Biallelic variants in RYR1 and STAC3 are predominant causes of King-Denborough Syndrome in an African cohort."
    },
    {
      "pmid": "21514828",
      "rank": 5,
      "score": 1.3,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/j.nmd.2011.03.006",
      "title": "King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene."
    },
    {
      "pmid": "37783627",
      "rank": 6,
      "score": 1.25,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/j.nmd.2023.09.003",
      "title": "Pancreatitis in RYR1-related disorders."
    },
    {
      "pmid": "2907859",
      "rank": 7,
      "score": 1.2499999999999998,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/0887-8994(86)90013-5",
      "title": "King-Denborough syndrome: contracture testing and literature review."
    },
    {
      "pmid": "27918309",
      "rank": 8,
      "score": 1.15,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1213/XAA.0000000000000421",
      "title": "Intraoperative Presentation of Malignant Hyperthermia (Confirmed by RYR1 Gene Mutation, c.7522C>T; p.R2508C) Leads to Diagnosis of King-Denborough Syndrome in a Child With Hypotonia and Dysmorphic Features: A Case Report."
    },
    {
      "pmid": "11345752",
      "rank": 9,
      "score": 1.1,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/11345752/",
      "title": "[Anesthetic management of the King-Denborough syndrome]."
    },
    {
      "pmid": "12364941",
      "rank": 10,
      "score": 0.9500000000000001,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1590/s0004-282x2002000500011",
      "title": "King-Denborough Syndrome: report of two Brazilian cases."
    },
    {
      "pmid": "1483040",
      "rank": 11,
      "score": 0.8999999999999999,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/0960-8966(92)90001-m",
      "title": "Malignant hyperthermia and neuromuscular disease."
    },
    {
      "pmid": "12826552",
      "rank": 12,
      "score": 0.85,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1007/BF03018646",
      "title": "Anesthetic management of a ventilator-dependent parturient with the King-Denborough syndrome."
    },
    {
      "pmid": "24951453",
      "rank": 13,
      "score": 0.7999999999999999,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/j.nmd.2014.05.003",
      "title": "RYR1-related congenital myopathy with fatigable weakness, responding to pyridostigimine."
    },
    {
      "pmid": "1508238",
      "rank": 14,
      "score": 0.75,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1002/mus.880150619",
      "title": "Dominantly inherited malignant hyperthermia (MH) in the King-Denborough syndrome."
    },
    {
      "pmid": "3245876",
      "rank": 15,
      "score": 0.65,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1016/0887-8994(88)90086-0",
      "title": "Congenital myopathy with cleft palate and increased susceptibility to malignant hyperthermia: King syndrome?"
    },
    {
      "pmid": "1415346",
      "rank": 16,
      "score": 0.6499999999999999,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1002/ajmg.1320430610",
      "title": "King syndrome: a genetically heterogenous phenotype due to congenital myopathies."
    },
    {
      "pmid": "18765655",
      "rank": 17,
      "score": 0.6,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1212/01.wnl.0000324929.33780.2f",
      "title": "King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene."
    },
    {
      "pmid": "3374516",
      "rank": 18,
      "score": 0.6,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1002/mus.880110507",
      "title": "Halothane-caffeine contracture testing in neuromuscular diseases."
    },
    {
      "pmid": "36965156",
      "rank": 19,
      "score": 0.5499999999999999,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://doi.org/10.1002/ajmg.a.63188",
      "title": "A novel RYR1 variant in an infant with a unique fetal presentation of central core disease."
    },
    {
      "pmid": "11758332",
      "rank": 20,
      "score": 0.4,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/11758332/",
      "title": "[Two pediatric cases of malignant hyperthermia caused by sevoflurane]."
    },
    {
      "pmid": "11596430",
      "rank": 21,
      "score": 0.3,
      "content_source": null,
      "has_content": false,
      "token_estimate": null,
      "preferred_url": "https://pubmed.ncbi.nlm.nih.gov/11596430/",
      "title": "[King syndrome]."
    }
  ],
  "snippets": [
    {
      "snippet_id": 1,
      "pmid": "33190635",
      "drug": "desflurane",
      "classification": "risk",
      "snippet_text": "The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (enhanced heat",
      "snippet_score": 9.34,
      "cues": [
        "malignant hyperthermia"
      ],
      "article_rank": 1,
      "article_score": 6.74,
      "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
      "citation_url": "https://doi.org/10.1186/s13395-020-00243-4",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 2,
      "pmid": "33190635",
      "drug": "sevoflurane",
      "classification": "risk",
      "snippet_text": "The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (e",
      "snippet_score": 9.34,
      "cues": [
        "malignant hyperthermia"
      ],
      "article_rank": 1,
      "article_score": 6.74,
      "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
      "citation_url": "https://doi.org/10.1186/s13395-020-00243-4",
      "content_source": "pmc-full-text"
    },
    {
      "snippet_id": 3,
      "pmid": "33190635",
      "drug": "succinylcholine",
      "classification": "risk",
      "snippet_text": "The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (enhanced heat response or EHS) [ 10 \u2013 12 ]. Variations in the RYR",
      "snippet_score": 9.34,
      "cues": [
        "malignant hyperthermia"
      ],
      "article_rank": 1,
      "article_score": 6.74,
      "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
      "citation_url": "https://doi.org/10.1186/s13395-020-00243-4",
      "content_source": "pmc-full-text"
    }
  ],
  "batches": [
    {
      "token_estimate": 827,
      "messages": [
        {
          "role": "system",
          "content": "You are a clinical evidence synthesis assistant. Summarise whether article snippets describe safety or risk relationships between drugs and the referenced condition. Only infer what is explicitly supported by the snippets."
        },
        {
          "role": "user",
          "content": "Condition: King denborough\nRelated terms: King Denborough syndrome, King syndrome\n\nRespond with valid JSON following this schema:\n{\n  \"condition\": \"string\",\n  \"drugs\": [\n    {\n      \"name\": \"string\",\n      \"assessments\": [\n        {\n          \"snippet_id\": \"string\",\n          \"article_pmid\": \"string\",\n          \"article_title\": \"string\",\n          \"relationship\": \"risk | safety | uncertain\",\n          \"confidence\": \"low | medium | high\",\n          \"summary\": \"string\"\n        }\n      ]\n    }\n  ]\n}\n\nFor each drug, synthesise concise assessments that explain the relationship with the condition using the provided snippet evidence.\nSet relationship to 'risk' or 'safety' when the snippet supports that conclusion; use 'uncertain' only when evidence is insufficient.\nConfidence must be one of: low, medium, high.\nUse the snippet_id exactly as provided and maintain the drug names verbatim.\nSnippets:\n1. snippet_id: 1\n   article_pmid: 33190635\n   article_title: Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.\n   drug: desflurane\n   classification: risk\n   score: 9.34\n   article_rank: 1\n   source_url: https://doi.org/10.1186/s13395-020-00243-4\n   cues: malignant hyperthermia\n   snippet: The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (enhanced heat\n2. snippet_id: 2\n   article_pmid: 33190635\n   article_title: Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.\n   drug: sevoflurane\n   classification: risk\n   score: 9.34\n   article_rank: 1\n   source_url: https://doi.org/10.1186/s13395-020-00243-4\n   cues: malignant hyperthermia\n   snippet: The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (e\n3. snippet_id: 3\n   article_pmid: 33190635\n   article_title: Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.\n   drug: succinylcholine\n   classification: risk\n   score: 9.34\n   article_rank: 1\n   source_url: https://doi.org/10.1186/s13395-020-00243-4\n   cues: malignant hyperthermia\n   snippet: The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (enhanced heat response or EHS) [ 10 \u2013 12 ]. Variations in the RYR\n\nReturn only JSON."
        }
      ],
      "snippets": [
        {
          "pmid": "33190635",
          "snippet_id": 1,
          "drug": "desflurane",
          "classification": "risk",
          "snippet_text": "The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (enhanced heat",
          "snippet_score": 9.34,
          "cues": [
            "malignant hyperthermia"
          ],
          "article_rank": 1,
          "article_score": 6.74,
          "citation_url": "https://doi.org/10.1186/s13395-020-00243-4",
          "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
          "content_source": "pmc-full-text",
          "token_estimate": 198
        },
        {
          "pmid": "33190635",
          "snippet_id": 2,
          "drug": "sevoflurane",
          "classification": "risk",
          "snippet_text": "The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (e",
          "snippet_score": 9.34,
          "cues": [
            "malignant hyperthermia"
          ],
          "article_rank": 1,
          "article_score": 6.74,
          "citation_url": "https://doi.org/10.1186/s13395-020-00243-4",
          "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
          "content_source": "pmc-full-text",
          "token_estimate": 197
        },
        {
          "pmid": "33190635",
          "snippet_id": 3,
          "drug": "succinylcholine",
          "classification": "risk",
          "snippet_text": "The purification of RyR1 Ca 2+ release channels in 1988 [ 4 ] and the subsequent discovery in 1991 of pathogenic RYR1 variants [ 5 ] led to the association of impaired Ca 2+ homeostasis with malignant hyperthermia (MH) susceptibility (MIM # 145600) [ 6 ]. MH is a potentially fatal disorder of skeletal muscle Ca 2+ regulation. MH episodes are triggered by exposure to certain volatile anesthetics (e.g., sevoflurane, desflurane) and depolarizing muscle relaxants (succinylcholine). MH episodes are characterized by uncontrolled muscle hypermetabolism, with a clinical presentation including hypercapnia, sinus tachycardia, masseter muscle rigidity, and hyperthermia [ 5 , 7 ]. Guidelines from the European Malignant Hyperthermia Group (EMHG) and Malignant Hyperthermia Association of the United States (MHAUS) continue to inform the use of anesthetic drugs in individuals susceptible to MH [ 8 , 9 ]. In certain cases, extreme heat conditions, fever, and/or exertion can result in symptoms that mimic MH episodes (enhanced heat response or EHS) [ 10 \u2013 12 ]. Variations in the RYR",
          "snippet_score": 9.34,
          "cues": [
            "malignant hyperthermia"
          ],
          "article_rank": 1,
          "article_score": 6.74,
          "citation_url": "https://doi.org/10.1186/s13395-020-00243-4",
          "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
          "content_source": "pmc-full-text",
          "token_estimate": 212
        }
      ]
    }
  ],
  "responses": [
    {
      "model": "gpt-4o-mini",
      "response_id": "chatcmpl-CUwf177aMBCDYCQinzT3zA5rVJWlW",
      "content": "{\n  \"condition\": \"King denborough\",\n  \"drugs\": [\n    {\n      \"name\": \"desflurane\",\n      \"assessments\": [\n        {\n          \"snippet_id\": \"1\",\n          \"article_pmid\": \"33190635\",\n          \"article_title\": \"Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.\",\n          \"relationship\": \"risk\",\n          \"confidence\": \"high\",\n          \"summary\": \"Desflurane is associated with triggering malignant hyperthermia episodes in susceptible individuals, indicating a risk relationship.\"\n        }\n      ]\n    },\n    {\n      \"name\": \"sevoflurane\",\n      \"assessments\": [\n        {\n          \"snippet_id\": \"2\",\n          \"article_pmid\": \"33190635\",\n          \"article_title\": \"Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.\",\n          \"relationship\": \"risk\",\n          \"confidence\": \"high\",\n          \"summary\": \"Sevoflurane is linked to the risk of malignant hyperthermia episodes in individuals with susceptibility, indicating a risk relationship.\"\n        }\n      ]\n    },\n    {\n      \"name\": \"succinylcholine\",\n      \"assessments\": [\n        {\n          \"snippet_id\": \"3\",\n          \"article_pmid\": \"33190635\",\n          \"article_title\": \"Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.\",\n          \"relationship\": \"risk\",\n          \"confidence\": \"high\",\n          \"summary\": \"Succinylcholine is identified as a trigger for malignant hyperthermia episodes in susceptible individuals, indicating a risk relationship.\"\n        }\n      ]\n    }\n  ]\n}",
      "parsed": {
        "condition": "King denborough",
        "drugs": [
          {
            "name": "desflurane",
            "assessments": [
              {
                "snippet_id": "1",
                "article_pmid": "33190635",
                "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
                "relationship": "risk",
                "confidence": "high",
                "summary": "Desflurane is associated with triggering malignant hyperthermia episodes in susceptible individuals, indicating a risk relationship."
              }
            ]
          },
          {
            "name": "sevoflurane",
            "assessments": [
              {
                "snippet_id": "2",
                "article_pmid": "33190635",
                "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
                "relationship": "risk",
                "confidence": "high",
                "summary": "Sevoflurane is linked to the risk of malignant hyperthermia episodes in individuals with susceptibility, indicating a risk relationship."
              }
            ]
          },
          {
            "name": "succinylcholine",
            "assessments": [
              {
                "snippet_id": "3",
                "article_pmid": "33190635",
                "article_title": "Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.",
                "relationship": "risk",
                "confidence": "high",
                "summary": "Succinylcholine is identified as a trigger for malignant hyperthermia episodes in susceptible individuals, indicating a risk relationship."
              }
            ]
          }
        ]
      },
      "usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 365,
        "total_tokens": 1683
      }
    }
  ]
}